P. Simon, M. P. Ramee, and R. Boulahrouz, Epidemiologic data of primary glomerular diseases in western France, Kidney International, vol.66, issue.3, pp.905-908, 2004.

P. Ronco and H. Debiec, Pathophysiological advances in membranous nephropathy: time for a shift in patient's care, The Lancet, vol.385, issue.9981, pp.1983-1992, 2015.

L. H. Beck, R. G. Bonegio, and G. Lambeau, M-type phospholipase A 2 receptor as target antigen in idiopathic membranous nephropathy, The New England Journal of Medicine, vol.361, issue.1, pp.11-21, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00417718

N. M. Tomas, L. H. Beck, and C. Meyer-schwesinger, Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy, The New England Journal of Medicine, vol.371, issue.24, pp.2277-2287, 2014.

C. Zaghrini, B. Seitz-polski, and J. Justino, Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy, Kidney International, vol.95, issue.3, pp.666-679, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02380896

A. Schieppati, L. Mosconi, and A. Perna, Prognosis of untreated patients with idiopathic membranous nephropathy, The New England Journal of Medicine, vol.329, issue.2, pp.85-89, 1993.

J. M. Hofstra, F. C. Fervenza, and J. F. Wetzels, Treatment of idiopathic membranous nephropathy, Nature Reviews Nephrology, vol.9, issue.8, pp.443-458, 2013.

P. Ruggenenti, P. Cravedi, and A. Chianca, Rituximab in idiopathic membranous nephropathy, Journal of the American Society of Nephrology, vol.23, issue.8, pp.1416-1425, 2012.

J. Radhakrishnan and D. C. Cattran, The KDIGO practice guideline on glomerulonephritis: reading between the (guide)-lines-application to the individual patient, Kidney International, vol.82, issue.8, pp.840-856, 2012.

J. Floege, S. J. Barbour, and D. C. Cattran, Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney International, vol.95, issue.2, pp.268-280, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02380922

N. M. Tomas, E. Hoxha, and A. T. Reinicke, Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy, The Journal of Clinical Investigation, vol.126, issue.7, pp.2519-2532, 2016.

J. M. Hofstra, L. H. Beck, D. M. Beck, J. F. Wetzels, and D. J. Salant, Anti-phospholipase A 2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy, Clinical journal of the American Society of Nephrology, vol.6, issue.6, pp.1286-1291, 2011.

B. Seitz-polski, C. Payré, and D. Ambrosetti, Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients, Dialysis, Transplantation, vol.29, issue.12, pp.2334-2342, 2014.

P. Ruggenenti, H. Debiec, and B. Ruggiero, Anti-phospholipase A 2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy, Journal of the American Society of Nephrology, vol.26, issue.10, pp.2545-2558, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02193793

B. Seitz-polski, G. Dolla, and C. Payré, Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy, Journal of the American Society of Nephrology, vol.27, issue.5, pp.1517-1533, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01455661

B. Seitz-polski, H. Debiec, and A. Rousseau, Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy, Journal of the American Society of Nephrology, vol.29, issue.2, pp.401-408, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02193807

B. Seitz-polski, K. Dahan, and H. Debiec, High-dose rituximab and early remission in PLA2R1-related membranous nephropathy, Clinical Journal of the American Society of Nephrology, vol.14, issue.8, pp.1173-1182, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02413171

D. J. Salant, Does epitope spreading influence responsiveness to rituximab in PLA2R-associated membranous 12 Journal of Immunology Research nephropathy?, Clinical Journal of the American Society of Nephrology, vol.14, issue.8, pp.1122-1124, 2019.

M. J. Walport, Complement. First of two parts, The New England Journal of Medicine, vol.344, issue.14, pp.1058-1066, 2001.

J. A. Schatz-jakobsen, D. V. Pedersen, and G. R. Andersen, Structural insight into proteolytic activation and regulation of the complement system, Immunological Reviews, vol.274, issue.1, pp.59-73, 2016.

D. J. Salant, C. Darby, and W. G. Couser, Experimental membranous glomerulonephritis in rats. Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals, The Journal of Clinical Investigation, vol.66, issue.1, pp.71-81, 1980.

A. V. Cybulsky, H. G. Rennke, I. D. Feintzeig, and D. J. Salant, Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy, The Journal of Clinical Investigation, vol.77, issue.4, pp.1096-1107, 1986.

A. Kuroki, T. Shibata, H. Honda, D. Totsuka, K. Kobayashi et al., Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy, Internal Medicine, vol.41, issue.11, pp.936-942, 2002.

H. Ohtani, H. Wakui, and A. Komatsuda, Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy, Nephrology, Dialysis, Transplantation, vol.19, issue.3, pp.574-579, 2004.

C. C. Huang, A. Lehman, and A. Albawardi, IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression, Modern Pathology, vol.26, issue.6, pp.799-805, 2013.

J. S. Van-der-zee, P. Van-swieten, and R. C. Aalberse, Inhibition of complement activation by IgG4 antibodies, Clinical and Experimental Immunology, vol.64, issue.2, pp.415-422, 1986.

M. H. Tao, S. M. Canfield, and S. L. Morrison, The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain, The Journal of Experimental Medicine, vol.173, issue.4, pp.1025-1028, 1991.

N. Hayashi, S. &. Akiyama, and H. Okuyama, Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese, Clinical and Experimental Nephrology, vol.19, issue.5, pp.797-803, 2015.

N. Hayashi, K. Okada, and Y. Matsui, Glomerular mannosebinding lectin deposition in intrinsic antigen-related membranous nephropathy, Nephrology, Dialysis, Transplantation, vol.33, issue.5, pp.832-840, 2018.

S. Bally, H. Debiec, and D. Ponard, Phospholipase A2 receptor-related membranous nephropathy and mannanbinding lectin deficiency, Journal of the American Society of Nephrology, vol.27, issue.12, pp.3539-3544, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02180286

C. Dähnrich, L. Komorowski, and C. Probst, Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy, Clinica Chimica Acta, vol.421, pp.213-218, 2013.

P. I. Terasaki and J. D. Mcclelland, Microdroplet assay of human serum cytotoxins, Nature, vol.204, issue.4962, pp.998-1000, 1964.

A. D. Kistler, G. Singh, and M. M. Altintas, Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease, Journal of Biological Chemistry, vol.288, issue.51, pp.36598-36609, 2013.

B. Seitz-polski, G. Dolla, and C. Payré, Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy, Biochimie, vol.118, pp.104-115, 2015.

J. M. Hofstra, H. Debiec, and C. D. Short, Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy, Journal of the American Society of Nephrology, vol.23, issue.10, pp.1735-1743, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00919117

F. Von-haxthausen, L. Reinhard, and H. O. Pinnschmidt, Antigen-specific IgG subclasses in primary and malignancyassociated membranous nephropathy, Frontiers in Immunology, vol.9, p.3035, 2018.

S. J. Warren, L. A. Arteaga, and L. A. Diaz, The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus, The Journal of Investigative Dermatology, vol.120, issue.1, pp.1-5, 2003.

G. Sinkovits, Á. Szilágyi, and P. Farkas, Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura, Frontiers in Immunology, vol.9, p.1646, 2018.

C. Seikrit, P. Ronco, and H. Debiec, Factor H autoantibodies and membranous nephropathy, The New England Journal of Medicine, vol.379, issue.25, pp.2479-2481, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02193814

Y. Segawa, S. Hisano, and M. Matsushita, IgG subclasses and complement pathway in segmental and global membranous nephropathy, Pediatric Nephrology, vol.25, issue.6, pp.1091-1099, 2010.

M. Vivarelli, F. Emma, and T. Pellé, Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies, Kidney International, vol.87, issue.3, pp.602-609, 2015.

W. Luo, F. Olaru, and J. H. Miner, Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy, Frontiers in Immunology, vol.9, p.1433, 2018.

Z. Wang, L. Wen, Y. Dou, and Z. Zhao, Human antithrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway, Bioscience Reports, vol.38, issue.3, 2018.

N. M. Tomas, C. Meyer-schwesinger, and H. Spiegel, A heterologous model of thrombospondin type 1 domaincontaining 7A-associated membranous nephropathy, Journal of the American Society of Nephrology, vol.28, issue.11, pp.3262-3277, 2017.

P. Ancian, G. Lambeau, and M. Lazdunski, Multifunctional activity of the extracellular domain of the M-type (180 kDa) membrane receptor for secretory phospholipases A2, Biochemistry, vol.34, issue.40, pp.13146-13151, 1995.

A. ?koberne, A. Behnert, and B. Teng, Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen, European Journal of Clinical Investigation, vol.44, issue.8, pp.753-765, 2014.

S. Takahashi, K. Watanabe, and Y. Watanabe, C-type lectinlike domain and fibronectin-like type II domain of 13 Journal of Immunology Research phospholipase A 2 receptor 1 modulate binding and migratory responses to collagen, FEBS Letters, vol.589, issue.7, pp.829-835, 2015.

M. Godel, F. Grahammer, and T. B. Huber, Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy, The New England Journal of Medicine, vol.372, issue.11, pp.1073-1075, 2015.

C. Meyer-schwesinger, G. Lambeau, and R. A. Stahl, Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy, The New England Journal of Medicine, vol.372, issue.11, pp.1073-1075, 2015.

I. Koneczny, A new classification system for IgG4 autoantibodies, Journal of Immunology Research, vol.9, issue.14, p.97, 2018.